Venture CapitalRIA · CRD 328461Exempt Reporting AdviserPrivate Fund Adviser

Updated:

Impellent Ventures

Impellent Ventures writes up to $1.5M into preseed and seed stage companies and aims to be a first check-in partner. The firm brings an operator-first...

Impellent Ventures logo

Impellent Ventures

Impellent Ventures writes up to $1.5M into preseed and seed stage companies and aims to be a first check-in partner. The firm brings an operator-first mentality from experience starting, building, growing, and selling companies. It is city agnostic and diversity-focused, investing anywhere in founders addressing major technology challenges.

General information

Firm type

Venture Capital

Year founded

2018

Location

Region

North America

Country

United States

City

Rochester

Corporate office

Rochester, NY, United States

Sector focus

Enterprise SoftwareAI/MLDigital HealthIndustrial TechRobotics & Automation

Frequently asked questions

How does Impellent Ventures source proprietary deal flow?

The firm benefits from direct proximity to the University of Rochester and Rochester Institute of Technology, two research universities with substantial patent output and spinout activity. This geographic embedding creates early access to technical founders in imaging science, robotics, and advanced manufacturing. The firm also syndicates with East Coast university-affiliated funds, expanding origination beyond the immediate Rochester market.

Does Impellent Ventures participate in fund commitments or only direct deals?

Available public record shows Impellent Ventures executing direct equity investments in operating companies. There is no documented participation in fund-of-funds commitments or secondary market activity. The firm's known posture is direct-check writing into seed, early-stage, and select growth financings.

What investment stages does Impellent Ventures typically target?

The firm concentrates on seed and early-stage rounds, with selective follow-on capital deployed in growth-stage extensions. Known deals include a 2022 security-drone robotics investment and a 2023 digital health product financing, both at the venture-stage inflection point where laboratory innovation meets commercial deployment.

Which sectors does Impellent Ventures explicitly avoid?

The firm has not published a formal negative sector screen. Its observed pattern favors deep-engineering products rooted in university intellectual property — enterprise software, industrial automation, applied AI, and digital health. Consumer internet, marketplaces, and pure-play financial technology are not represented in known portfolio disclosures.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on venture capital firms?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

Browse by category

More Rochester Venture Capital profiles